Evaluation of use of proton pump inhibitors in Greece

European Journal of Internal Medicine

Volumn 20, Issue 2, 2009, Pages 171-173

  Ntaios, George ^a   Chatzinikolaou, Anastasia ^a   Kaiafa, Georgia ^a   Savopoulos, Christos ^a   Hatzitolios, Apostolos ^a   Karamitsos, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Gastroesophageal reflux disease; Helicobacter pylori; Non steroidal anti inflammatory drugs; Peptic ulcer disease

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; STEROID; STOMACH SECRETION INHIBITOR; WARFARIN;

ARTICLE; CONTROLLED STUDY; GASTROESOPHAGEAL REFLUX; GREECE; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; STOMACH DISEASE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION; GASTROESOPHAGEAL REFLUX; GREECE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; OMEPRAZOLE; PEPTIC ULCER; PHYSICIAN'S PRACTICE PATTERNS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; STOMACH DISEASES;

EID: 62649109380     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2007.10.020     Document Type: Article

References (13)

1. Barrison A.F., Jarboe L.A., Weinberg B.M., Nimmagadda K., Sullivan L.M., and Wolfe M.M. Patterns of proton pump inhibitor use in clinical practice. Am J Med 111 (2001) 469-473
2. Howden C.W., Henning J.M., Huang B., Lukasik N., and Freston J.W. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am J Gastroenterol 96 (2001) 1704-1710
3. Caro J.J., Salas M., and Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 23 (2001) 998-1017
4. Prescription Pricing Authority. PPA Annual report 1996-7: Newcastle: Prescription Pricing Authority: 1997: 27.
5. AstraZeneca. Annual Report and Form 20-F, 2000. London, England: AstraZeneca 2001. Available at: http://www.astrazeneca.annualrep2000/default1.asp. Accessed June 3, 2004.
6. Blankenhorn K., and Lipson D. Business watch: 2001 in review: despite economic challenges, pharmaceutical industry still maintains steady growth. Med Mark Med 37 (2002) 46-62
7. Walker N.M., and McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 23 3 (2001) 116-117
8. Parente F., Cucino C., Gallus S., Bargiggia S., Greco S., Pastore L., et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther 17 (2003) 1503-1506
9. Naunton M., Peterson G.M., and Bleasel M.D. Overuse of proton pump inhibitors. J Clin Pharm Ther 25 (2000) 333-340
10. Pillans P.I., Kubler P.A., Radford J.M., and Overland V. Concordance between use of proton pump inhibitors and prescribing guidelines. Med J Aust 172 (2000) 16-18
11. Sebastian S.S., Kernan N., Qasim A., O'Morain C.A., and Buckley M. Appropriateness of gastric antisecretory therapy in hospital practice. Ir J Med Sci 172 3 (Jul-Sep 2003) 115-117
12. De Burgas Lunar C., Novo del Castillo S., Llorente Díaz E., and Salinero Fort M.A. Study of prescription-indication of proton pump inhibitors. Rev Clin Esp 206 6 (Jun 2006) 266-270
13. Noguerando Asensio A., Rodríguez Barrientos R., Zelaya Castro P., Sánchez Sempere A., Antuña Blanco F., Lutz García E., et al. Use of acid-suppressive medications in hospitalized patients. Ann Med Intern 19 11 (Nov 2002) 557-560